Status:
RECRUITING
Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborating Sponsors:
Daiichi Sankyo
Conditions:
Atrial Fibrillation
Recurrent Venous Thromboembolism
Eligibility:
All Genders
18+ years
Brief Summary
MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Design: single-center, observational, prospective, uncontrol...
Detailed Description
Population: Patients over 18 years of age, with recurrent atrial fibrillation or venous thromboembolism, already anticoagulated with any DOAC or patients who initiate therapy with DOAC and who give th...
Eligibility Criteria
Inclusion
- · Patients older than 18 years.
- With atrial fibrillation or recurrent venous thrombosis.
- In chronic treatment with any DOAC type drug.
- Patients who sign the informed consent
Exclusion
- Patients who do not guarantee collaboration.
- Patients with advanced cognitive impairment and not supervised.
- Patients with alcoholism.
- Patients with psychiatric disorder and not supervised
Key Trial Info
Start Date :
July 29 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT04042155
Start Date
July 29 2019
End Date
August 1 2024
Last Update
February 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, Spain, 08025